CN103562180B - 新型六氢环戊二烯并吡咯酮，六氢吡咯并吡咯酮，八氢吡咯并吡啶酮和八氢吡啶酮化合物 - Google Patents

新型六氢环戊二烯并吡咯酮，六氢吡咯并吡咯酮，八氢吡咯并吡啶酮和八氢吡啶酮化合物 Download PDF

Info

Publication number
CN103562180B
CN103562180B CN201280023662.XA CN201280023662A CN103562180B CN 103562180 B CN103562180 B CN 103562180B CN 201280023662 A CN201280023662 A CN 201280023662A CN 103562180 B CN103562180 B CN 103562180B
Authority
CN
China
Prior art keywords
phenyl
octahydro
trifluoromethoxy
pyrrolo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280023662.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103562180A (zh
Inventor
奥理莉亚·康特
丹尼尔·洪齐格
维尔纳·奈德哈特
马蒂亚斯·内特科文
坦贾·舒尔兹-加施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN103562180A publication Critical patent/CN103562180A/zh
Application granted granted Critical
Publication of CN103562180B publication Critical patent/CN103562180B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CN201280023662.XA 2011-05-17 2012-05-14 新型六氢环戊二烯并吡咯酮，六氢吡咯并吡咯酮，八氢吡咯并吡啶酮和八氢吡啶酮化合物 Expired - Fee Related CN103562180B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166437.1 2011-05-17
EP11166437 2011-05-17
PCT/EP2012/058852 WO2012156339A1 (en) 2011-05-17 2012-05-14 New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds

Publications (2)

Publication Number Publication Date
CN103562180A CN103562180A (zh) 2014-02-05
CN103562180B true CN103562180B (zh) 2016-04-20

Family

ID=46124329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280023662.XA Expired - Fee Related CN103562180B (zh) 2011-05-17 2012-05-14 新型六氢环戊二烯并吡咯酮，六氢吡咯并吡咯酮，八氢吡咯并吡啶酮和八氢吡啶酮化合物

Country Status (11)

Country Link
US (1) US8501768B2 (https=)
EP (1) EP2709984B1 (https=)
JP (1) JP2014513703A (https=)
KR (1) KR20140042814A (https=)
CN (1) CN103562180B (https=)
BR (1) BR112013028368A2 (https=)
CA (1) CA2832334A1 (https=)
ES (1) ES2537591T3 (https=)
MX (1) MX346980B (https=)
RU (1) RU2013153898A (https=)
WO (1) WO2012156339A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
WO2015048507A1 (en) 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CA2979534A1 (en) * 2015-03-13 2016-09-22 Abbvie Inc. (indazol-4-yl)hexahydropyrrolopyrrolones and method of use
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1371369A (zh) * 1999-09-04 2002-09-25 阿文蒂斯药物德国有限公司 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其作为脂酶抑制剂的用途
CN1416424A (zh) * 2000-03-07 2003-05-07 阿文蒂斯药物德国有限公司 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其抑制激素敏感性脂酶的用途
CN101115741A (zh) * 2005-02-15 2008-01-30 诺和诺德公司 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
CN101432265A (zh) * 2006-04-25 2009-05-13 伊莱利利公司 11-β-羟类固醇脱氢酶1的抑制剂
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436943A1 (en) * 2000-12-01 2003-06-06 Cerep Sa Hydantoin compounds useful as anti-inflammatory agents
AU2008248996A1 (en) * 2007-04-27 2008-11-13 Sanofi-Aventis 2 -heteroaryl- pyrrolo [3, 4-C] pyrrole derivatives and their use as SCD inhibitors
ES2585806T3 (es) * 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1371369A (zh) * 1999-09-04 2002-09-25 阿文蒂斯药物德国有限公司 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其作为脂酶抑制剂的用途
CN1416424A (zh) * 2000-03-07 2003-05-07 阿文蒂斯药物德国有限公司 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其抑制激素敏感性脂酶的用途
CN101115741A (zh) * 2005-02-15 2008-01-30 诺和诺德公司 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
CN101432265A (zh) * 2006-04-25 2009-05-13 伊莱利利公司 11-β-羟类固醇脱氢酶1的抑制剂
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pyrrolopyrazinedione-Based Inhibitors of Human Hormone-Sensitive Lipase;Deborah H. Slee,等;《Journal of Medicinal Chemistry》;20030228;第46卷(第7期);第1120-1122页 *

Also Published As

Publication number Publication date
WO2012156339A1 (en) 2012-11-22
US8501768B2 (en) 2013-08-06
BR112013028368A2 (pt) 2017-01-24
ES2537591T3 (es) 2015-06-09
US20120295934A1 (en) 2012-11-22
HK1191942A1 (zh) 2014-08-08
CN103562180A (zh) 2014-02-05
EP2709984B1 (en) 2015-03-18
CA2832334A1 (en) 2012-11-22
MX2013011628A (es) 2013-10-25
MX346980B (es) 2017-04-07
JP2014513703A (ja) 2014-06-05
RU2013153898A (ru) 2015-06-27
KR20140042814A (ko) 2014-04-07
EP2709984A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
CN103562180B (zh) 新型六氢环戊二烯并吡咯酮，六氢吡咯并吡咯酮，八氢吡咯并吡啶酮和八氢吡啶酮化合物
EP1501803B1 (en) Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
CA2701150C (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
DK3074400T3 (en) Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
MX2012010826A (es) Derivados espiro azaciclicos como inhibidores de lipasa sensible a hormonas (hsl).
CN102317289A (zh) 作为β分泌酶抑制剂的内酰胺
CN103429569B (zh) 氮杂螺环癸酮化合物
EP2688881B1 (en) New azaspirodecanone compounds as hsl inhibitors
HK1191942B (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6126080B2 (ja) 新規ヘキサヒドロピロロイミダゾロン化合物
WO2025245351A1 (en) Substituted aryl sulfonamides and compositions and uses thereof
HK1191326B (en) Azaspirodecanone compounds
HK1191946B (en) New hexahydropyrroloimidazolone compounds
HK1191327B (en) Azaspirodecanone compounds as hsl inhibitors
HK1190706A1 (en) Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes
HK1176607B (en) Azacyclic spiroderivatives as hsl inhibitors
HK1190706B (en) Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes
HK1206722A1 (en) New bicyclic derivatives
HK1206722B (en) New bicyclic derivatives
HK1181760A1 (zh) 氮杂环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191942

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191942

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

Termination date: 20180514